Considering the results from our therapeutic strategy targeting STAT1 in Th1 cells or Th17 cells, ndSTAT1-TMD can be an effective and new therapeutic reagent for treating various autoimmune diseases associated with pathogenic Th1 and Th17 cells. Here, STAT1 is linked to autoimmune disease.